Vir Biotechnology reports data from MARCH Phase 2 clinical study

Vir Biotechnology (VIR) announced 24-week post-end of treatment data from Part B of the ongoing MARCH Phase 2 clinical study evaluating tobevibart and elebsiran without or with pegylated interferon alpha, or PEG-IFNalpha, in participants with chronic hepatitis B, or CHB. The study-defined primary endpoint, proportion of participants with undetectable hepatitis B surface antigen, or HBsAg, at 24 weeks post-end of treatment, was achieved by 17% and 21% of participants with baseline HBsAgless than1,000 IU/mL receiving tobevibart and elebsiran without or with PEG-IFNalpha, respectively. The detailed data were presented today at the European Association for the Study of the Liver, or EASL, congress in Amsterdam. CHB is a long-lasting, inflammatory liver disease caused by the hepatitis B virus, or HBV. Participants in the trial received tobevibart and elebsiran without or with PEG-IFNalpha. Tobevibart was administered at 300 mg every 4 weeks; elebsiran, at 200 mg every 4 weeks; and PEG-IFNalpha, for patients receiving it, at 180 microgram weekly. Participants with HBsAg loss after 48 weeks of treatment who met eligibility criteria discontinued both NRTI ide reverse transcriptase inhibitor) as well as tobevibart and elebsiran without or with PEG-IFNalpha treatment. As previously communicated, Phase 3 development of combinations of tobevibart and elebsiran in CHB will not move forward without a global development and commercialization partner, which has not been secured. The Company plans to streamline the final stages of the MARCH Phase 2 program to ensure continued participant benefit and safety, while applying continued financial stewardship. Cash runway guidance into mid-2027 remains unchanged, based on the current operating plan.